Intratumoral delivery of TransCon(™) TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction

BACKGROUND: Intratumoral (IT) delivery of toll-like receptor (TLR) agonists has shown encouraging anti-tumor benefit in preclinical and early clinical studies. However, IT delivery of TLR agonists may lead to rapid effusion from the tumor microenvironment (TME), potentially limiting the duration of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zúñiga, Luis Alejandro, Leßmann, Torben, Uppal, Karan, Bisek, Nicola, Hong, Enping, Rasmussen, Caroline E., Karlsson, Jens-Jakob, Zettler, Joachim, Holten-Andersen, Lars, Bang, Kathy, Thakar, Dhruv, Lee, Yu-Chi, Martinez, Salomon, Sabharwal, Simran Singh, Stark, Sebastian, Faltinger, Frank, Kracker, Oliver, Weisbrod, Samuel, Müller, Robin, Voigt, Tobias, Bigott, Kornelia, Tabrizifard, Mohammad, Breinholt, Vibeke Miller, Mirza, Amer M., Rosen, David B., Sprogøe, Kennett, Punnonen, Juha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484246/
https://www.ncbi.nlm.nih.gov/pubmed/36123697
http://dx.doi.org/10.1186/s12935-022-02708-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484246/
https://www.ncbi.nlm.nih.gov/pubmed/36123697
http://dx.doi.org/10.1186/s12935-022-02708-6

Ejemplares similares